Moderna Stock Price

-10.22 (-6.1%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 11,801,340
Bid Price 157.10
Ask Price 157.80
News (2)
Day High 171.2543


52 Week Range


Day Low 157.29
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Moderna Inc MRNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-10.22 -6.1% 157.30 20:00:01
Open Price Low Price High Price Close Price Prev Close
166.23 157.29 171.2543 160.07 167.52
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
180,385 11,801,340 $ 161.90 $ 1,910,644,381 - 117.3411 - 497.17
Last Trade Time Type Quantity Stock Price Currency
19:59:42 formt 100 $ 157.30 USD


Draw Mode:

Moderna Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 63.78B 405.45M 297.32M $ 803.40M $ 523.25M -1.95 10.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -847.58k 5.70%

more financials information »

Moderna News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week204.01212.76157.29182.7410,812,464-46.71-22.9%
1 Month242.99259.1989157.29219.409,214,359-85.69-35.26%
3 Months344.49376.4118157.29268.5812,271,270-187.19-54.34%
6 Months298.87497.17157.29340.8314,417,691-141.57-47.37%
1 Year125.20497.17117.3411274.2812,867,07232.1025.64%
3 Years16.62497.1711.54150.2111,099,201140.68846.45%
5 Years22.00497.1711.54149.3710,760,992135.30615.0%

Moderna Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.